IN8bio (INAB) Competitors $0.28 +0.02 (+8.35%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INAB vs. EPIX, SKYE, ASRT, TLSA, INCR, TNXP, BGM, GALT, GNTA, and PYRGFShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include ESSA Pharma (EPIX), Skye Bioscience (SKYE), Assertio (ASRT), Tiziana Life Sciences (TLSA), InterCure (INCR), Tonix Pharmaceuticals (TNXP), Qilian International Holding Group (BGM), Galectin Therapeutics (GALT), Genenta Science (GNTA), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. ESSA Pharma Skye Bioscience Assertio Tiziana Life Sciences InterCure Tonix Pharmaceuticals Qilian International Holding Group Galectin Therapeutics Genenta Science PyroGenesis Canada IN8bio (NASDAQ:INAB) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Which has stronger earnings & valuation, INAB or EPIX? ESSA Pharma is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$0.75-0.34ESSA PharmaN/AN/A-$28.54M-$0.64-2.63 Does the media refer more to INAB or EPIX? In the previous week, ESSA Pharma had 19 more articles in the media than IN8bio. MarketBeat recorded 20 mentions for ESSA Pharma and 1 mentions for IN8bio. ESSA Pharma's average media sentiment score of 0.07 beat IN8bio's score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the news media. Company Overall Sentiment IN8bio Neutral ESSA Pharma Neutral Which has more volatility & risk, INAB or EPIX? IN8bio has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Does the MarketBeat Community favor INAB or EPIX? ESSA Pharma received 325 more outperform votes than IN8bio when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 72.73% of users gave IN8bio an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2472.73% Underperform Votes927.27% ESSA PharmaOutperform Votes34975.87% Underperform Votes11124.13% Do analysts recommend INAB or EPIX? IN8bio currently has a consensus price target of $7.75, indicating a potential upside of 2,953.59%. ESSA Pharma has a consensus price target of $9.50, indicating a potential upside of 465.48%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe IN8bio is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in INAB or EPIX? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 15.5% of IN8bio shares are owned by company insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is INAB or EPIX more profitable? ESSA Pharma's return on equity of -21.64% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% ESSA Pharma N/A -21.64%-21.02% SummaryESSA Pharma beats IN8bio on 9 of the 14 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.19M$3.05B$5.67B$9.11BDividend YieldN/A1.81%5.28%4.00%P/E Ratio-0.3445.4186.2418.04Price / SalesN/A288.281,023.8582.26Price / CashN/A188.9637.4433.55Price / Book0.444.095.124.76Net Income-$30.01M-$41.02M$108.98M$223.10M7 Day Performance-5.23%1.96%0.47%0.18%1 Month Performance-12.90%-4.73%-0.94%-1.98%1 Year Performance-79.70%-0.63%26.68%23.41% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.2308 of 5 stars$0.28+8.4%$7.75+2,718.2%-80.6%$19.93MN/A-0.3720Negative NewsGap UpEPIXESSA Pharma3.5028 of 5 stars$1.78+0.9%$9.50+435.2%-82.6%$78.79MN/A-2.7750Upcoming EarningsShort Interest ↓News CoverageSKYESkye Bioscience0.987 of 5 stars$2.55-6.6%$18.67+632.0%-27.4%$78.58MN/A0.0011News CoveragePositive NewsGap UpASRTAssertio2.7671 of 5 stars$0.82-2.8%$3.25+296.8%+4.5%$78.20M$152.07M-1.1220TLSATiziana Life Sciences1.392 of 5 stars$0.74-6.6%N/A+28.1%$78.00MN/A0.008Positive NewsINCRInterCure1.3391 of 5 stars$1.69-2.9%N/A+36.3%$77.06M$96.61M0.00350Positive NewsGap UpTNXPTonix Pharmaceuticals3.0874 of 5 stars$0.41+6.8%$53.50+12,980.7%-98.6%$76.63M$7.77M-0.0150Analyst ForecastNews CoverageGap DownBGMQilian International Holding GroupN/A$10.55-0.9%N/AN/A$76.28M$46.47M0.00298Positive NewsGALTGalectin Therapeutics1.0595 of 5 stars$1.22-0.4%$11.00+805.3%-29.0%$76.25MN/A-1.669GNTAGenenta Science2.0134 of 5 stars$4.13-0.6%$25.00+506.1%-0.3%$75.45MN/A0.007Gap UpPYRGFPyroGenesis CanadaN/A$0.41-2.0%N/A+9.7%$74.95M$9.14M-6.7890 Related Companies and Tools Related Companies EPIX Competitors SKYE Competitors ASRT Competitors TLSA Competitors INCR Competitors TNXP Competitors BGM Competitors GALT Competitors GNTA Competitors PYRGF Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INAB) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
